Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 16NETWORK 2INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Other 1

Conditions

Prostatic Neoplasms 2Urinary Incontinence 1Sexual Dysfunction, Physiological 1Erectile Dysfunction 1

Interventions

Radiotherapy 299Cisplatin 263Cyclophosphamide 229Doxorubicin 176Paclitaxel 166Vincristine 160Carboplatin 149Filgrastim 139Etoposide 139Gemcitabine 118Fluorouracil 113Docetaxel 112Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 91Leucovorin 90Granulocyte Colony-Stimulating Factor 74Specimen Handling 65Magnetic Resonance Spectroscopy 61Capecitabine 59Irinotecan 58Radiation 54Ifosfamide 51Oxaliplatin 48Daunorubicin 48Temozolomide 47Radiotherapy, Conformal 47Platinum 47Peripheral Blood Stem Cell Transplantation 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Interventional × Tadalafil × Clear all
NCT07576335 2026-05-08

ROBOPREP

Surgical Outcomes Research Centre (SOuRCe)

Phase 2 Not yet recruiting
64 enrolled
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms, Urinary Incontinence

NCT00931528 2018-02-14

Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy

Radiation Therapy Oncology Group

Phase 3 Completed
242 enrolled 13 charts
GenitourinaryOther

Prostatic Neoplasms, Sexual Dysfunction, Physiological

Data powered by HemOnc (CC BY 4.0) Colophon âš¡